ANP 231
Alternative Names: ANP-231Latest Information Update: 01 Apr 2021
At a glance
- Originator AlphaNavi Pharma
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 16 Mar 2021 Preclinical trials in Pain in Japan (unspecified route), prior to March 2021 (AlphaNavi Pharma pipeline, March 2021)